Vítor H. Alves

Dr. Vítor H. Alves

ICNAS - Institute for Nuclear Sciences Applied to Health, Coimbra, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2017 in Modern Physics Letters A
Verified
Journal Article
Closed access
PDF file
Francisco AlvesFrancisco Alves
Francisco Alves
Vítor H. AlvesVítor H. Alves
Vítor H. Alves
SCSergio J.C. Do Carmo
Sergio J.C. Do Carmo
ANA. C. B. Neves
A. C. B. Neves
MSM. Silva
M. Silva
AAAntero Abrunhosa
Antero Abrunhosa

3 July 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ABARNAB BANERJEE
ARNAB BANERJEE
Vítor H. AlvesVítor H. Alves
Vítor H. Alves
TRTiago Rondão
Tiago Rondão
JSJosé Sereno
José Sereno
ÂNÂngela Neves
Ângela Neves
LFLino Ferreira
Lino Ferreira
Here we report a two-step surface modification methodology to radiolabel small extracellular vesicles (SEVs) with 64CuCl2 for PET/MRI imaging. The modification did not change or damage the morphology, surface receptor proteins and internal RNA content. Radiolabeled SEVs could be detected in organs with low accumulation such as the brain (0.4–0.5% ID g−1) and their brain location determined by MRI.

14 September 2018 in Instruments
Verified
Journal Article
Open access
PDF file
Vítor H. AlvesVítor H. Alves
Vítor H. Alves
SCSergio J.C. Do Carmo
Sergio J.C. Do Carmo
Francisco AlvesFrancisco Alves
Francisco Alves
AAAntero Abrunhosa
Antero Abrunhosa
An automated process for the production and purification of radiometals produced by irradiating liquid targets in a medical cyclotron, using a commercially available module, has been developed. The method is suitable for the production and purification of radiometals such as 68Ga, 64Cu and 61Cu through irradiation of liquid targets and is important for producing high specific activity radioisotopes with a substantial reduction in processing time and cost when compared with the solid target approach. The “liquid target” process also eliminates the need for pre- and post-irradiation target preparation and simplifies the transfer of irradiated material from target to hotcell. A 68GaCl3 solution can be obtained in about 35 min with an average yield of 73.9 ± 6.7% in less than 10 mL of volume. 64CuCl2 solutions can be obtained with an average yield of 81.2 ± 7.8% in about 1 h of processing time. A dedicated single-use disposable kit is used on a commercial IBA Synthera® extension module.

7 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Alexandra Isabel FonsecaAlexandra Isabel Fonseca
Alexandra Isabel Fonseca
Vítor H. AlvesVítor H. Alves
Vítor H. Alves
SCSergio J.C. Do Carmo
Sergio J.C. Do Carmo
MSMagda Silva
Magda Silva
Ivanna HrynchakIvanna Hrynchak
Ivanna Hrynchak
AAAntero Abrunhosa
Antero Abrunhosa
PET imaging has gained significant momentum in the last few years, especially in the area of oncology, with an increasing focus on metal radioisotopes owing to their versatile chemistry and favourable physical properties. Copper-61 (t1/2 = 3.33 h, 61% β+, Emax = 1.216 MeV) provides unique advantages versus the current clinical standard (i.e., gallium-68) even though, until now, no clinical amounts of 61Cu-based radiopharmaceuticals, other than thiosemicarbazone-based molecules, have been produced. This study aimed to establish a routine production, using a standard medical cyclotron, for a series of widely used somatostatin analogues, currently labelled with gallium-68, that could benefit from the improved characteristics of copper-61. We describe two possible routes to produce the radiopharmaceutical precursor, either from natural zinc or enriched zinc-64 liquid targets and further synthesis of [61Cu]Cu-DOTA-NOC, [61Cu]Cu-DOTA-TOC and [61Cu]Cu-DOTA-TATE with a fully automated GMP-compliant process. The production from enriched targets leads to twice the amount of activity (3.28 ± 0.41 GBq vs. 1.84 ± 0.24 GBq at EOB) and higher radionuclidic purity (99.97% vs. 98.49% at EOB). Our results demonstrate, for the first time, that clinical doses of 61Cu-based radiopharmaceuticals can easily be obtained in centres with a typical biomedical cyclotron optimised to produce 18F-based radiopharmaceuticals.

11 November 2018 in Molecules
Verified
Journal Article
Open access
PDF file
JGJoana F Guerreiro
Joana F Guerreiro
Vítor H. AlvesVítor H. Alves
Vítor H. Alves
AAAntero Abrunhosa
Antero Abrunhosa
António PauloAntónio Paulo
António Paulo
OGOctávia Monteiro Gil
Octávia Monteiro Gil
Filipa MendesFilipa Mendes
Filipa Mendes
64CuCl2 has recently been proposed as a promising agent for prostate cancer (PCa) theranostics, based on preclinical studies in cellular and animal models, and on the increasing number of human studies documenting its use for PCa diagnosis. Nevertheless, the use of 64CuCl2 raises important radiobiological questions that have yet to be addressed. In this work, using a panel of PCa cell lines in comparison with a non-tumoral prostate cell line, we combined cytogenetic approaches with radiocytotoxicity assays to obtain significant insights into the cellular consequences of exposure to 64CuCl2. PCa cells were found to exhibit increased 64CuCl2 uptake, which could not be attributed to increased expression of the main copper cellular importer, hCtr1, as had been previously suggested. Early DNA damage and genomic instability were also higher in PCa cells, with the tumoral cell lines exhibiting deficient DNA-damage repair upon exposure to 64CuCl2. This was corroborated by the observation that 64CuCl2 was more cytotoxic in PCa cells than in non-tumoral cells. Overall, we showed for the first time that PCa cells had a higher sensitivity to 64CuCl2 than healthy cells, supporting the idea that this compound deserved to be further evaluated as a theranostic agent in PCa.

10 March 2021 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
ÂNÂngela C. B. Neves
Ângela C. B. Neves
IHIvanna Hrynchak
Ivanna Hrynchak
IFInês Fonseca
Inês Fonseca
Vítor H. AlvesVítor H. Alves
Vítor H. Alves
MPMariette M. Pereira
Mariette M. Pereira
AAAntero Abrunhosa
Antero Abrunhosa
The neurotracer 6-[18F]FDOPA has been, for many years, a powerful tool in PET imaging of neuropsychiatric diseases, movement disorders and brain malignancies. More recently, it also demonstrated good results in the diagnosis of other malignancies such as neuroendocrine tumours, pheochromocytoma or pancreatic adenocarcinoma.The multiple clinical applications of this tracer fostered a very strong interest in the development of new and improved methods for its radiosynthesis. The no-carrier-added nucleophilic 18F-fluorination process has gained increasing attention, in recent years, due to the high molar activities obtained, when compared with the other methods although the radiochemical yield remains low (17–30%). This led to the development of several nucleophilic synthetic processes in order to obtain the product with molar activity, radiochemical yield and enantiomeric purity suitable for human PET studies.Automation of the synthetic processes is crucial for routine clinical use and compliance with GMP requirements. Nevertheless, the complexity of the synthesis makes the production challenging, increasing the chance of failure in routine production. Thus, for large-scale clinical application and wider use of this radiopharmaceutical, progress in the automation of this complex radiosynthesis is of critical importance.This review summarizes the most recent developments of 6-[18F]FDOPA radiosynthesis and discusses the key issues regarding its automation for routine clinical use.